Company facts
- Industry
- Pharmaceutical Preparations
- Headquarters
- Parsippany, New Jersey
- Most recent report
- 8-K, filed Aug 6, 2026
- Filings on record
- 1,013+ filings
- On EDGAR
- CIK 1555280
- Fiscal year ends
- December
- Filer status
- Large accelerated filer
Financials 8 of 27
News 8 of 83
- 8-K Leadership change Aug 6, 2026
- 8-K Quarterly results Aug 6, 2026
- 8-K Leadership change May 22, 2026
- 8-K Current report on a material event May 20, 2026
- 8-K Quarterly results May 7, 2026
- 8-K Quarterly results Feb 12, 2026
- 8-K Current report on a material event Feb 5, 2026
- 8-K Significant contract Dec 18, 2025
Prospectuses and Registrations 8 of 12
- 424B3 Prospectus supplement for an offering Aug 12, 2025
- FWP Free writing prospectus Aug 11, 2025
- 424B3 Prospectus supplement for an offering Aug 11, 2025
- S-3ASR Automatic shelf registration Aug 5, 2025
- 424B2 Prospectus supplement for an offering Nov 10, 2022
- FWP Free writing prospectus Nov 8, 2022
- 424B3 Prospectus supplement for an offering Nov 8, 2022
- S-8 Registration statement for an employee plan Aug 5, 2022
Proxies 8 of 20
- DEFA14A Extra proxy material Apr 8, 2026
- DEF 14A Proxy statement for a shareholder vote Apr 8, 2026
- DEFA14A Extra proxy material Apr 9, 2025
- DEF 14A Proxy statement for a shareholder vote Apr 9, 2025
- DEFA14A Extra proxy material May 8, 2024
- DEFA14A Extra proxy material May 6, 2024
- DEFA14A Extra proxy material Apr 10, 2024
- DEF 14A Proxy statement for a shareholder vote Apr 10, 2024
Ownership 8 of 850
- 4 Insider reported a trade Sep 2, 2026
- 3 Insider reported their initial holding Aug 24, 2026
- 4 Insider reported a trade Aug 11, 2026
- SCHEDULE 13G/A Large holder reported a passive stake, amended Jul 30, 2026
- 4 Insider reported a trade Jul 14, 2026
- 4 Insider reported a trade Jul 14, 2026
- 4 Insider reported a trade Jul 14, 2026
- 4 Insider reported a trade Jul 14, 2026
Other 8 of 21
- 11-K Employee stock plan report Jun 22, 2026
- SD Conflict minerals disclosure May 28, 2026
- ARS Annual report sent to shareholders Apr 8, 2026
- 11-K Employee stock plan report Jun 23, 2025
- SD Conflict minerals disclosure Jun 2, 2025
- ARS Annual report sent to shareholders Apr 9, 2025
- 11-K Employee stock plan report Jun 26, 2024
- SD Conflict minerals disclosure May 30, 2024
What to read: Jun 2026 10-Q
SECSift found 2 of 13 sections worth reading, with 0 positive, 5 notable, and 3 negative flags.
Financial Statements (Item 1)
Full financial statements with material changes in earnings, cash, and litigation.Management's Discussion (Item 2)
MD&A shows real quarterly results, segment trends, debt, FX, and tariff exposure.Notable- Restructuring charges surged to $77 million in Q2 2026 from $30 million, driven by employee termination costs.
- International segment revenue up 12% total, 7% operational in H1 2026, boosted by FX and price increases.
- New $1.25 billion revolving credit facility (Aug 2030) replaced prior facility; no amounts drawn as of June 30, 2026.
- $2.0 billion 0.250% convertible notes issued Dec 2025; proceeds used for $1.8 billion share repurchases through March 2026.
- Share repurchase authorization had $1.3 billion remaining as of June 30, 2026.
What changed: Jun 2026 vs. Mar 2026
About 12% of ZTS's Jun 2026 10-Q is new information. 62 paragraphs were added, 145 changed, and 19 removed. Below are the most important lines SECSift identified.
Removed
Everything here comes from Zoetis Inc.'s own filings on SEC EDGAR. The filing list is rechecked every hour. SECSift analysis was completed on Aug 20, 2026, from the 10-Q for Jun 2026.